The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 08, 2023
Filed:
Feb. 02, 2021
Applicant:
Vella Bioscience, Inc., Worcester, MA (US);
Inventors:
Harin Padma-Nathan, Los Angeles, CA (US);
MIchael Frid, Medford, MA (US);
Helen Segil, Worcester, MA (US);
Nial Chase DeMena, Worceseter, MA (US);
Assignee:
Vella Bioscience, Inc., Worcester, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/05 (2006.01); A61K 31/5575 (2006.01); A61K 36/88 (2006.01); A61K 31/4985 (2006.01); A61K 31/417 (2006.01); A61K 38/12 (2006.01); A61K 31/352 (2006.01); A61K 9/127 (2006.01); A61P 15/10 (2006.01); A61K 9/00 (2006.01); A61K 31/55 (2006.01); A61K 31/137 (2006.01); A61K 31/53 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/568 (2006.01); A61K 31/13 (2006.01); A61K 31/475 (2006.01); A61K 31/496 (2006.01); A61K 31/4458 (2006.01); A61K 31/472 (2006.01);
U.S. Cl.
CPC ...
A61K 31/05 (2013.01); A61K 9/0034 (2013.01); A61K 9/127 (2013.01); A61K 31/13 (2013.01); A61K 31/137 (2013.01); A61K 31/352 (2013.01); A61K 31/417 (2013.01); A61K 31/4458 (2013.01); A61K 31/472 (2013.01); A61K 31/475 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 31/55 (2013.01); A61K 31/5575 (2013.01); A61K 31/568 (2013.01); A61K 36/88 (2013.01); A61K 38/12 (2013.01); A61P 15/10 (2018.01);
Abstract
The invention relates to compositions and methods containing hemp and/or-derived cannabidiol (CBD) for topical use in treating female sexual dysfunction induced by antidepressants, including, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other anti-depressants.